BioXcel Therapeutics, Inc. (BTAI) has a consensus analyst rating of Buy, based on 15 analysts covering the stock. Of those, 8 recommend buying, 6 recommend holding, and 1 recommend selling.
The analyst consensus price target for BTAI is $12.00, representing a +1,042.9% upside from the current price of $1.05. Price targets range from a low of $1.00 to a high of $25.00.
